ArticleTherapeutic advances in hematology2026
Hypo-fractionated radiotherapy combined with PD-1 inhibitor for relapsed/refractory B-cell lymphoma after failure to CD19 CAR-T therapy.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell lymphoma relapsed after chimeric antigen receptor (CAR) T-cell therapy lacks effective standard treatment options and generally has a poor prognosis, largely due to mechanisms such as immune escape and tumor heterogeneity. Radiotherapy combined with immune checkpoint inhibitors (ICIs) may exert synergistic effects, including local tumor control through radiation-induced DNA damage and systemic immune activation via modulation of the tumor immune microenvironment. This case report describes a patient with relapsed/refractory (R/R) B-cell lymphoma who experienced multiple relapses and treatment failures, including CD19 CAR-T therapy. Almost 7 years after CAR-T treatment, the patient developed disease relapse and was diagnosed with follicular lymphoma (FL). The patient received a personalized treatment strategy combining hypo-fractionated radiotherapy (30 Gy/5 fractions) and the Programmed Death-1 (PD-1) inhibitor camrelizumab, achieving complete remission (CR) and remaining disease-free for over 43 months. This case highlights the potential efficacy of this combination strategy in R/R lymphoma, particularly in patients with limited treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.